Reports Q2 revenue $318.18M, consensus $313.12M. Chris Simon, Haemonetics’ CEO, stated: “In our second quarter we continued to strengthen our momentum and industry leadership, delivering growth while broadening our global presence. Our planned acquisition of OpSens, Inc. creates powerful opportunities for accelerated growth and diversification, and we are committed to supporting the long-term success of our businesses through continued strategic portfolio evolution and additional growth investments.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HAE:
- Haemonetics 2nd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website
- HAE Upcoming Earnings Report: What to Expect?
- Opsens downgraded to Market Perform from Outperform at Raymond James
- Haemonetics Corporation Announces Definitive Agreement to Acquire OpSens, Inc.
- Haemonetics to acquire Opsens for C$2.90 per share in cash, sees accretion
